Semaglutide
The groundbreaking GLP-1 receptor agonist that has transformed treatment for type 2 diabetes and obesity. Marketed as Ozempic, Wegovy, and Rybelsus.
28 min read · Last updated March 2026 · 25+ clinical trial citations
FDA-Approved Prescription Medication: Semaglutide is approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). This guide is for educational purposes - consult your healthcare provider.
Key Takeaways
Overview
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It belongs to a class of medications known as incretin mimetics, which replicate and enhance the effects of naturally occurring gut hormones involved in glucose metabolism and appetite regulation.
GLP-1 is an incretin hormone secreted by L-cells in the intestinal mucosa in response to food intake. Under normal physiological conditions, native GLP-1 has a half-life of only 1-2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered to resist this enzymatic breakdown while maintaining high receptor affinity and potency.
FDA Approval History
Formulations
Brand Names Explained
Ozempic
Subcutaneous · Diabetes
The original subcutaneous semaglutide formulation approved for improving glycemic control in type 2 diabetes.
- Week 1-4: 0.25 mg weekly
- Week 5-8: 0.5 mg weekly
- Week 9+: 1 mg weekly (optional)
- Maximum: 2 mg weekly
Wegovy
Subcutaneous · Weight Loss
Higher-dose formulation specifically approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities.
- Week 1-4: 0.25 mg weekly
- Week 5-8: 0.5 mg weekly
- Week 9-12: 1.0 mg weekly
- Week 13-16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly
Rybelsus
Oral · Diabetes
First oral GLP-1 receptor agonist. Uses SNAC absorption enhancer for gastric absorption. Daily dosing required.
- Take on empty stomach upon waking
- Swallow whole with ≤4 oz water
- Wait 30 min before eating/drinking
- Doses: 3mg → 7mg → 14mg
Mechanism
How Semaglutide Works
Multiple interconnected mechanisms through GLP-1 receptor activation
Pancreatic Effects
Enhances insulin release only when glucose is elevated, dramatically reducing hypoglycemia risk.
Reduces glucagon secretion when glucose is high, decreasing hepatic glucose production.
May promote beta cell proliferation and inhibit apoptosis (preclinical evidence).
Central Nervous System Effects
Activates GLP-1 receptors in hypothalamus, reducing hunger and increasing satiety signals.
May shift preferences away from high-fat, energy-dense foods toward healthier options.
Emerging research suggests effects on mesolimbic reward processing beyond food.
Delayed Gastric Emptying
Slows stomach emptying, reducing postprandial glucose spikes and promoting prolonged satiety.
Cardiovascular Benefits
Reduces blood pressure, improves lipids, decreases inflammation, reduces visceral fat.
Renoprotection
FLOW trial showed 24% reduction in kidney disease progression in diabetes patients.
Metabolic Improvement
Enhances insulin sensitivity, reduces hepatic fat, improves overall metabolic health.
Evidence
Clinical Research Overview
Robust clinical trial data across diabetes, obesity, and cardiovascular outcomes
SUSTAIN Trials (Type 2 Diabetes)
8 Phase 3 TrialsSTEP Trials (Weight Loss)
Pivotal for Wegovy1,961 adults with obesity or overweight with comorbidities
Extended treatment over 104 weeks
SELECT Trial: Cardiovascular Outcomes
17,604 participants · 40 months follow-up · Landmark Results
These results led to expanded FDA approval of Wegovy for cardiovascular risk reduction in patients with obesity and established cardiovascular disease.
Efficacy
Weight Loss Research
The weight loss achieved with semaglutide 2.4 mg represents a significant advancement in pharmacological obesity treatment, approaching levels previously achievable only with bariatric surgery for some patients.
Timeline of Effects
Weight Loss Composition
Higher proportion of fat loss compared to diet-only interventions
Weight Maintenance Critical
This reflects obesity as a chronic condition requiring ongoing treatment, similar to hypertension or diabetes.
Administration
Dosage Information
Subcutaneous (Ozempic/Wegovy)
Oral (Rybelsus)
Safety
Side Effects and Safety Profile
Boxed Warning: Thyroid C-Cell Tumors
In rodent studies, semaglutide caused thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Relevance to humans is unknown.
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Gastrointestinal Effects (Most Common)
Other Important Safety Concerns
Incidence ~0.1-0.3%. Discontinue promptly if suspected.
Cholelithiasis in 1.5-2.5%, cholecystitis ~0.5-1%. Higher with greater weight loss.
Low risk alone; increases with insulin or sulfonylureas.
May worsen with rapid glycemic improvement. Monitor if existing.
Considerations
"Ozempic Face" and Muscle Loss
"Ozempic Face"
Media term describing facial volume loss and sagging that accompanies significant weight loss.
- Loss of subcutaneous facial fat
- Skin laxity due to reduced volume
- Not unique to semaglutide - occurs with any rapid weight loss
- • Slower weight loss may reduce severity
- • Dermal fillers can restore volume
- • Weight maintenance prevents progression
Muscle Loss Concerns
20-25% of weight lost with semaglutide is lean mass. Prevention is important.
- Adequate protein intake (1.0-1.2 g/kg ideal body weight minimum)
- Resistance training throughout treatment
- Consider slower weight loss in elderly or sarcopenic patients
- Monitor functional status, not just scale weight
Contraindications
Who Should NOT Use Semaglutide
Absolute Contraindications
Precautions/Relative Contraindications
Pregnancy: Discontinue at least 2 months before planned conception.
Comparisons
Semaglutide vs Tirzepatide vs Retatrutide
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 agonist | GIP/GLP-1 dual agonist | GLP-1/GIP/Glucagon triple |
| Approval Status | FDA Approved | FDA Approved | Investigational |
| Weight Loss | 15-17% | 20-22% | 22-24% (Phase 2) |
| HbA1c Reduction | 1.5-1.8% | 2.0-2.4% | ~2.2% (Phase 2) |
| CV Outcomes Data | Yes (SELECT) | Pending | No |
| Oral Option | Yes (Rybelsus) | No | No |
| Safety Track Record | Most extensive | Moderate | Limited |
Treatment selection should consider individual patient factors including glycemic goals, weight loss needs, cardiovascular risk, tolerability, and cost/access.
FAQ
Frequently Asked Questions
References
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN 6)
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults (STEP 3). JAMA. 2021;325(14):1403-1413.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. (SELECT)
- Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
- Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15-30.
- Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Mol Metab. 2021;46:101102.
- Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19(9):1242-1251.
- Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. (STEP-HFpEF)
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. (FLOW)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. 2023.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. 2024.
- U.S. Food and Drug Administration. Rybelsus (semaglutide) Prescribing Information. 2023.
Disclaimer: This article is for educational and informational purposes only and is not intended as medical advice. Semaglutide is an FDA-approved prescription medication that should only be used under the supervision of a licensed healthcare provider. Consult a qualified healthcare professional before starting any medication or treatment.
Last updated: March 2026 · Reviewed by: Scientific Aminos Editorial Board
Order Semaglutide Wholesale
US-manufactured, HPLC verified. Available for distributors, telehealth providers, clinics, and research institutions.